ImmunityBio Investors Face May 26 Deadline in Securities Class Action Over FDA Ad Rebuke

Overview

• Several plaintiff firms are inviting shareholders to seek lead‑plaintiff status by Tuesday, May 26, 2026.
• Douglas v. ImmunityBio, Inc., No. 2:26‑cv‑03261, is pending in the U.S. District Court for the Central District of California.
• The complaint alleges executives made false or misleading claims about Anktiva, including calling it a “cancer vaccine,” and names Executive Chairman Dr. Patrick Soon‑Shiong.
• The lawsuit followed an FDA warning letter, dated March 13 and publicized March 24, that said a TV ad and a podcast for Anktiva were false or misleading under federal law.
• After the letter became public, ImmunityBio shares fell about 21% to close at $7.42 on March 24.